<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203810</url>
  </required_header>
  <id_info>
    <org_study_id>btph-044-2019-ERS09</org_study_id>
    <nct_id>NCT04203810</nct_id>
  </id_info>
  <brief_title>Effectiveness and Tolerability of Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)</brief_title>
  <official_title>Effectiveness and Tolerability of Ectoin® Mouth and Throat Spray Althaea Honey (ERS09) Compared to Saline Spray in Patients Suffering From Sore Throat Due to Acute Pharyngitis and Dry Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bitop AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bitop AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this multicentre, actively controlled, randomized, open label, parallel group,
      prospective, comparator study is to collect data on the clinical effectiveness and
      tolerability of the medical device ERS09 compared to a well-established comparator spray in
      the symptomatic treatment of sore throat due to acute pharyngitis and dry cough.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to collect data on the clinical effectiveness and tolerability of
      Ectoin® Mouth and Throat Spray Althaea Honey (ERS09) compared to the well-established
      comparator spray EMSER® Hals- und Rachenspray (both medical devices) in the symptomatic
      treatment of sore throat due to acute pharyngitis and dry cough.

      The principle mode of action of ectoine is based on the physical interaction of the
      compatible solute with water and the resulting stabilizing effects of the ectoine hydro
      complex on the epithelial tissue treated. Althaea has so-called mucilaginous effects, that
      means generally a shielding of the irritated mucus membranes by thin polysaccharide layers.
      Such mucilaginous polymer layers lead to rehydration, coating of peripheral sensory
      receptors, and therefore to a reduction of throat irritation and dry coughing. Honey acts
      predominantly as demulcent with its viscous liquid constitution based on mainly fructose and
      glucose. The combination of all three substances may result in a multi-modal treatment of the
      symptoms of sore throat and dry cough.

      Patients will be randomly assigned to one of the following treatment groups:

        -  treatment with ERS09

        -  treatment with comparator (EMSER® Hals- und Rachenspray)

      Patients' symptoms will be documented by the physician in investigator questionnaires at
      visits 1, 2 and 3. At visit 1 the patients will receive a patient diary for daily
      documentation of their symptoms. In addition, patients and investigators will be asked to
      evaluate the overall effectiveness and tolerability of ERS09 spray at visit 3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of mean total symptom score</measure>
    <time_frame>7 days</time_frame>
    <description>Baseline adjusted mean change of patient's assessment of total symptom score (patient diary) averaged over 7 treatment days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of daily symptom score</measure>
    <time_frame>1 day</time_frame>
    <description>Baseline adjusted daily change of patient's assessment of total symptom score (patient diary)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE) and serious adverse events (SAE) during treatment phase</measure>
    <time_frame>7 +/- 2 days</time_frame>
    <description>Evaluation of severity, nature and frequency of AEs/SAEs and their relationship to the investigational devices</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Sore Throat</condition>
  <condition>Acute Pharyngitis</condition>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>Ectoin® Mouth and Throat Spray Althaea Honey</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EMSER® Hals- und Rachenspray (throat spray)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 to 3 puffs to be administered several times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ectoin® Mouth and Throat Spray Althaea Honey (ERS09)</intervention_name>
    <description>4 puffs to be administered as needed several times a day for patients aged ≥ 12 years. A maximum of 10 applications per day should not be exceeded.</description>
    <arm_group_label>Ectoin® Mouth and Throat Spray Althaea Honey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EMSER® Hals-und Rachenspray (throat spray)</intervention_name>
    <description>1 to 3 puffs to be administered several times a day</description>
    <arm_group_label>EMSER® Hals- und Rachenspray (throat spray)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must sign and date an Informed Consent consistent with International
             Conference on Harmonisation (ICH)/Good Clinical Practice (GCP)/ISO14155 guidelines and
             local regulation prior to participation in the trial

          -  Individuals regardless of gender 12 years old or older

          -  Patients with sore throat due to acute pharyngitis and dry cough, both with an onset
             of symptoms no more than 72 hours prior to Visit 1

          -  Sore Throat Pain Intensity Score ≥ 40 mm (measured on a 100 mm visual analogue scale
             [VAS])

        Exclusion Criteria:

          -  Hypersensitivity to Ectoin, Althaea off., Honey or any of the other ingredients of the
             ERS09 or the comparator

          -  Fructose intolerance or glucose-galactose malabsorption

          -  Pregnant or breast-feeding women

          -  Suspected bacterial pharyngitis

          -  Individuals younger than 12 years

          -  Symptoms since more than 72 hours

          -  Use of any pain or cough medication (i.e. analgesic/ anti-pyretic/ anti-inflammatory
             or mucolytic/ expectorant/ antitussive) within 24 hours preceding enrolment in the
             study

          -  Oral lesions or oral surgical procedures within 1 month prior to enrolment in the
             study

          -  Patients for who the Investigator believes will not comply with the study protocol
             (e.g. patients with drug abuse or with a history of a serious psychiatric disorder as
             well as patients unwilling to give informed consent or to abide by the requirements of
             the protocol)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Moesges, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ClinCompetence GmbH, Genter Str. 7, 50672 Cologne, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ursula Pieper-Fuerst, PhD</last_name>
    <phone>+49 221 71613318</phone>
    <email>ursula.pieper-fuerst@clincompetence.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Werkhaeuser, PhD</last_name>
    <phone>+49 231 98 77 44 0</phone>
    <email>nina.werkhaeuser@bitop.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dr. Pasch</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Pasch, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Sondermann</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Sondermann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Männer</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Männer, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Kienle-Gogolok</name>
      <address>
        <city>Bad Schönborn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kienle-Gogolok, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Ginko</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ginko, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis für Hals-Nasen-Ohren-Heilkunde</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Praxis für Hals-Nasen-Ohren-Heilkunde</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Thieme</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Thieme, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Horn</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Horn, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Lenzenhuber</name>
      <address>
        <city>Jülich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Lenzenhuber, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Vent</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Vent, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Konzelmann</name>
      <address>
        <city>Röthenbach</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uta Konzelmann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reiber</name>
      <address>
        <city>Schorndorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Reiber</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

